DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....
Abaloparatide
WALTHAM, Mass., Dec. 21, 2014 (GLOBE NEWSWIRE) — Radius Health, Inc. today announced positive top-line 18-month fracture results from the Company’s Phase 3 clinical trial (ACTIVE) evaluating the investigational drug abaloparatide-SC for potential use in the reduction of fractures in postmenopausal osteoporosis.
https://in.finance.yahoo.com/news/radius-announces-positive-phase-3-042531179.html
Abaloparatide
BA058
BIM-44058
UNII-AVK0I6HY2U
BA058; BIM-44058; CAS 247062-33-5
MW 3960.5896, MF C174 H300 N56 O49
NAME………C2.29-methyl(22-L-glutamic acid(F>E),23-L-leucine(F>L),25-L-glutamic acid(H>E),26-L-lysine(H>K),28-L-leucine(I>L),30-L-lysine(E>K),31-L-leucine(I>L))human parathyroid hormone-related protein-(1-34)-proteinamide
L-Alaninamide, L-alanyl-L-valyl-L-seryl-L-alpha-glutamyl-L-histidyl-L-glutaminyl-L-leucyl-L-leucyl-L-histidyl-L-alpha-aspartyl-L-lysylglycyl-L-lysyl-L-seryl-L-isoleucyl-L-glutaminyl-L-alpha-aspartyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-alpha-glutamyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-lysyl-L-leucyl-L-leucyl-2-methylalanyl-L-lysyl-L-leucyl-L-histidyl-L-threonyl-
L-Alaninamide, L-alanyl-L-valyl-L-seryl-L-α-glutamyl-L-histidyl-L-glutaminyl-L-leucyl-L-leucyl-L-histidyl-L-α-aspartyl-L-lysylglycyl-L-lysyl-L-seryl-L-isoleucyl-L-glutaminyl-L-α-aspartyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-α-glutamyl-L-leucyl-L-leucyl-L-α-glutamyl-L-lysyl-L-leucyl-L-leucyl-2-methylalanyl-L-lysyl-L-leucyl-L-histidyl-L-threonyl-
CLINICAL……….https://clinicaltrials.gov/search/intervention=Abaloparatide%20OR%20BA058%20OR%20BIM-44058
BIM-44058 is a 34 amino acid analog of native human PTHrP currently in phase III clinical trials at Radius Health for the treatment of postmenopausal osteoporosis. Radius is also developing a microneedle transdermal patch using a 3M drug delivery system in phase II clinical trials. The drug candidate was originally developed at Biomeasure (a subsidiary of Ipsen), and was subsequently licensed to Radius and Teijin Pharma.
………………………….
PATENT
http://www.google.com/patents/EP2206725A1?cl=en
-
A peptide of the formula:[Glu22, 25, Leu23, 28, 31, Lys26, Aib29, Nle30]hPTHrP(1-34)NH2;[Glu22, 25, Leu23, 28, 30, 31, Lys26, Aib29]hPTHrP(1-34)NH2; [Glu22, 25,29, Leu23, 28, 30, 31, Lys26]hpTHrP(1-34)NH2; [Glu22, 25, 29, Leu23, 28, 31, Lys26, Nle30]hPTHrP(1-34)NH2; [Ser1, Ile5, Met8, Asn10, Leu11, 23, 28, 31, His14, Cha15, Glu22, 25, Lys26, 30, Aib29]hPTHrP (1-34)NH2; [Cha22, Leu23, 28, 31, Glu25, 29, Lys26, Nle30]hPTHrP(1-34)NH2; [Cha7, 11, 15]hPTHrP(1-34)NH2; [Cha7, 8, 15]hPTHrP(1-34)NH2; [Glu22, Leu23, 28, Aib25, 29, Lys26]hpTHrP(1-34)NH2; [Aib29]hPTHrP(1-34)NH2; [Glu22, 25, Leu23, 28, 31, Lys26, Aib29, 30]hPTHrP(1-34)NH2; [Glu22, 25, Leu23, 28, 31, Lys26, Aib29]hPTHrP(1-34)NH2; [Glu22, 25, Leu23, 28, 31, Aib26, 29, Lys30] hPTHrP(1-34)NH2; or [Leu27, Aib29]hPTH(1-34)NH2; or a pharmaceutically acceptable salt thereof.
…………………
SEE……http://www.google.com.ar/patents/US8148333?cl=en
………………..
SEE…………http://www.google.im/patents/US20090227498?cl=pt
| EP5026436A | Title not available | |||
| US3773919 | Oct 8, 1970 | Nov 20, 1973 | Du Pont | Polylactide-drug mixtures |
| US4767628 | Jun 29, 1987 | Aug 30, 1988 | Imperial Chemical Industries Plc | Polylactone and acid stable polypeptide |
| WO1994001460A1 * | Jul 13, 1993 | Jan 20, 1994 | Syntex Inc | Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis |
| WO1994015587A2 | Jan 5, 1994 | Jul 21, 1994 | Steven A Jackson | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| WO1997002834A1 * | Jul 3, 1996 | Jan 30, 1997 | Biomeasure Inc | Analogs of parathyroid hormone |
| WO1997002834A1 * | 3 Jul 1996 | 30 Jan 1997 | Biomeasure Inc | Analogs of parathyroid hormone |
| WO2008063279A2 * | 3 Oct 2007 | 29 May 2008 | Radius Health Inc | A stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof |
| US5695955 * | 23 May 1995 | 9 Dec 1997 | Syntex (U.S.A.) Inc. | Gene expressing a nucleotide sequence encoding a polypeptide for treating bone disorder |
| US20030166836 * | 6 Nov 2002 | 4 Sep 2003 | Societe De Conseils De Recherches Et D’application Scientefiques, S.A.S., A France Corporation | Analogs of parathyroid hormone |
| US20050282749 * | 14 Jan 2005 | 22 Dec 2005 | Henriksen Dennis B | Glucagon-like peptide-1 (GLP-1); immunotherapy; for treatment of obesity |
New Drug Approvals 